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Careful assessment of risks and benefits has to precede each decision on allogeneic red blood cell
(RBC) transfusion. Currently, a number of key issues in transfusion medicine are highly con-
troversial, most importantly the influence of different transfusion thresholds on clinical outcome.
The aim of this article is to review current evidence on blood transfusions, to highlight ‘hot topics’
with respect to efficacy, outcome and risks, and to provide the reader with transfusion guidelines.
In addition, a brief synopsis of transfusion alternatives will be given. Based on up-to-date informa-
tion of current evidence, together with clinical knowledge and experience, the physician will be
able to make transfusion decisions that bear the lowest risk for the patient.
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Efficacy of allogeneic red blood cell
transfusions
A thorough knowledge of oxygen transport and the physiol-
ogy of anaemia is still considered to be the most important
factor in guiding decisions on red blood cell (RBC) transfu-
sions.31 Thus we emphasize some basic principles.
Oxygen transport
Oxygen supply has to be adequately matched to tissue oxy-
gen needs to ensure aerobic cell respiration. Whole-body
oxygen delivery (DO2) is the product of blood flow or cardiac
output (CO) and arterial oxygen content (Cao2 ):
Do2=CO·Cao2
where DO2 is expressed in ml min
1, CO in l min1 and
Cao2 in ml l
1.
Cao2 is the sum of haemoglobin-bound oxygen and
oxygen dissolved in plasma:
Cao2=ðSao2·k1·½HbÞ+ðk2·Pao2Þ
where Sao2 (%) is the arterial oxygen saturation, k1=
1.34 ml g1 is the oxygen-carrying capacity of haemoglobin,
[Hb] (g l1) is the haemoglobin concentration, k2=0.23 ml
l1 kPa1 is the plasma oxygen dissolution coefficient at
body temperature and Pao2 (kPa) is the partial pressure
of oxygen of arterial blood. Thus the complete formula
describing oxygen delivery is
Do2=CO·ðfSao2·k1·½Hbg+fk2·Pao2gÞ:
Under physiological conditions (when breathing air),
most of the oxygen (>98%) is bound to haemoglobin and
the amount dissolved in plasma (<2%) is of relatively minor
importance. However, in cases of extreme haemodilution,
ventilation with 100% oxygen (hyperoxic ventilation)
changes this relationship dramatically. Since the plasma
compartment in haemodiluted patients is significantly aug-
mented, hyperoxic ventilation will result in a substantial
increase in physically dissolved oxygen. It has been
shown that at haemoglobin concentrations as low as 3 g dl1,
physically dissolved oxygen contributes up to 74% of oxygen
consumption (VO2)
28 and reduces mortality significantly.51
Therefore hyperoxic ventilation has been proposed as an
additional method of reducing the need for allogeneic RBC
transfusions in cases of blood loss.26
It is important to note that blood flow, which is one of the
key determinants of DO2, is regulated not only at the level of
the central circulation (as represented by CO in the formula
above), but also at the regional level (blood flow between
organs) and the microcirculatory level (blood flow within
organs).54 Under physiological conditions DO2
(800–1200 ml min1) exceeds VO2 (200–300 ml min
1)
by a factor of up to 4, resulting in an oxygen extraction
ratio (O2ER=VO2/DO2) of 20–30%. Consequently, even a
marked isolated decrease in haemoglobin concentration
with all other determinants of DO2 remaining constant
will still result in sufficient DO2 to meet tissue oxygen
requirements. However, below a critical threshold of hae-
moglobin concentration there will be a decrease not only in
DO2 but also in VO2. This relationship between VO2 and DO2
is referred to as the concept of critical DO2 (Do2crit): above
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Do2crit tissue oxygenation is sufficient as represented by a
constant VO2 which is thus ‘DO2 independent’. In contrast,
below Do2crit oxygen demands are no longer met, resulting
in a decrease in VO2. This state is characterized by a
‘VO2–DO2 dependency’ and the development of tissue
hypoxia.40 This leads to an important question: Which
physiological mechanisms compensate for a decrease in
haemoglobin concentration in anaemia in order to maintain
DO2 above Do2crit?
Physiological adaptation to normovolaemic
anaemia
Surgical blood loss and trauma are major reasons for blood
transfusion.82 One of the main goals in patients with blood
loss is to maintain normovolaemia. Therefore we will
assume that hypovolaemia has been corrected and will
refer to the situation of normovolaemic anaemia.
Adaptative responses to a decrease in haemoglobin con-
centration include blood flow alterations at the central,
regional and microcirculatory level, and a shift in the oxy-
haemoglobin dissociation curve. The resulting key determi-
nants for adaptation to anaemia are an increase in CO,
redistribution of blood flow between organs and an increase
in O2ER.
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Regulation of blood flow at the level of the central cir-
culation is determined by CO. In response to anaemia, the
increase in CO is due mainly to two mechanisms: reduced
blood viscosity and increased sympathetic stimulation of the
heart. The decrease in blood viscosity due to the lower
haemoglobin concentration leads to an increased venous
return and thus to an increased preload. Another conse-
quence of the lower blood viscosity is a decrease in systemic
vascular resistance and afterload.31 Increased sympathetic
activity leads to an increase in myocardial contractility
which contributes significantly to increased CO.27 An
increase in the heart rate in response to increased sympa-
thetic activity is only relevant in humans receiving no med-
ication.40 95 In contrast, in anaesthetized humans the heart
rate does not seem to respond to anaemia.40 76 95 Therefore
the increase in CO in response to normovolaemic anaemia in
anaesthetized patients is primarily due to an augmented
stroke volume, and an increase in heart rate should be
considered as a sign of hypovolaemia.
The regional adaptation of blood flow in response to
anaemia comprises redistribution from non-vital to vital
organs, such as the heart and brain, which is mediated by
the adrenergic system. This is especially important for the
myocardium which physiologically has a high O2ER with a
relatively small oxygen extraction reserve. Thus, DO2 to the
heart is primarily increased by augmenting coronary blood
flow, in contrast with the brain which is also able to increase
O2ER significantly. In addition, in response to the elevated
blood flow to the microcirculation, the homogeneity of the
capillary bed is augmented. This occurs with respect to both
changes over time (temporal heterogeneity) and differences
between vessels (spatial heterogeneity), as only about one-
third of capillaries are perfused under normal conditions.
The resulting homogeneity leads to an increased O2ER.
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Finally, owing to increased synthesis of 2,3-diphosphogly-
cerate (2,3-DPG) in red cells, the oxyhaemoglobin dissocia-
tion curve shifts to the right, thus allowing more
haemoglobin-bound oxygen to be released at a given oxygen
partial pressure.31
Rationale and efficacy of RBC transfusions
In view of the mechanisms of adaptation to anaemia, what is
the rationale behind RBC transfusions, and is their efficacy
proven?
The rationale underlying RBC transfusion should not only
aim at increasing Cao2 and thus DO2, but essentially at
increasing VO2, thereby restoring adequate tissue oxygena-
tion.71 IncreasingDO2 without a concomitant increase in VO2
would indicate the absence ofVO2–DO2 dependency and thus
any increase in DO2 would be, strictly from a physiological
point of view, of questionable relevance.71 He´bert and
colleagues30 identified 18 studies examining the effect of
RBC transfusions on oxygenation variables. While in all
studies there was a significant increase in haemoglobin con-
centration in response to blood transfusion, in four of them
there was no increase in DO2. Furthermore, in the other 14
studies with an increase in DO2, a parallel increase in VO2
was detected in only five.30 This lack of increase in VO2 after
RBC transfusion could be explained by the absence of an
oxygen debt prior to infusion. Indeed, there is evidence from
experimental studies that pre-existing VO2–DO2 dependency,
and thus tissue hypoxia, was followed by an increase in VO2
after RBC transfusion.20 59 This prompts us to ask whether
there are factors that identify patients who are likely to react
favourably, i.e. who increase VO2 upon RBC transfusion.
Casutt and colleagues13 examined 67 cardiac surgery
patients who received a total of 170 RBC transfusions. Mea-
surements were performed approximately 5 h before and
after RBC transfusions. It was found that pretransfusion
haemoglobin, preoperative ejection fraction and age were
unrelated to individual responses in cardiac index (CI), DO2
and VO2 after RBC transfusion. In contrast, variables related
to oxygen delivery and oxygen consumption correlated with
individual responses to RBC transfusions and allowed better
prediction with regard to an increase in CI, DO2 and VO2. In
particular, a low oxygen consumption index correlated very
well with an increase in VO2 after transfusion. Similarly,
another study of patients evaluated whole-body O2ER as
a parameter for guiding transfusion decisions.67 Seventy
patients undergoing coronary artery bypass graft (CABG)
surgery with a postoperative hematocrit of 25% were
included. O2ER was monitored without influencing transfu-
sion decisions. Retrospectively, it was analysed whether an
O2ER of 45% as a transfusion trigger would have changed
decision-making. Of the 41 patients who received at least
one allogeneic RBC transfusion, seven had a postoperative
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O2ER of 45%, while only three of the 35 patients who were
not transfused reached this physiological transfusion trigger.
Thus it was concluded that whole-body O2ER might be a
helpful variable in a transfusion algorithm.67
Alternatively, one might argue that impaired functionality
of stored RBCs could be a reason for the lack of increase in
VO2 after RBC transfusion.
71 During storage, RBCs undergo
a variety of changes which are summarized under the term
‘storage lesions’.60 These include a decrease in 2,3-DPG,
ATP depletion and the release of proinflammatory sub-
stances. This results in a leftward shift of the oxyhaemoglo-
bin dissociation curve (i.e. increased oxygen affinity),
impaired RBC deformability and inflammatory reactions
in the transfusion recipient.57 60 In particular, the decrease
in 2,3-DPG levels and RBC deformability suggest a
decreased efficacy of ‘old’ RBCs and thus a failure to
increase VO2 after transfusion. It has been shown that,
after 2 weeks of storage, priming of neutrophils by agents
released from RBC units becomes significant.69 The results
of a study of critically ill patients with sepsis50 are in accor-
dance with this finding. Measurements were made before
and after transfusion of three units of RBCs. RBC transfu-
sions did not result in an increase in systemic VO2. Interest-
ingly, splanchnic ischaemia occurred in patients receiving
RBC units that were >15 days old.50 In a retrospective study,
Purdy and colleagues65 studied 31 critically ill septic
patients. It was found that the non-survivors (19 patients),
although not differing in the incidence of septic shock, Acute
Physiology and Chronic Health Evaluation II (APACHE II)
score, intensive care unit (ICU), length of hospital stay
(LOS), age and number of RBC units transfused compared
with survivors, were transfused with significantly older
RBCs (24 versus 21 days, P<0.0001). In an analysis of
medical records of CABG surgery patients, it was found
that the age of RBCs was a predictor for postoperative infec-
tion and pneumonia.87 In contrast, a prospective observa-
tional study in cardiac surgery patients could only identify
storage for >28 days, but not the mean age of transfused
RBC units, as a predictor of pneumonia.43 However, recent
reviews have concluded that current evidence on the effect
of storage duration of RBCs is insufficient and that addi-
tional trials are necessary.36 57 Surprisingly, a recent pro-
spective randomized study in 22 critically ill patients did
not detect any difference in adverse events after transfusion
of RBCs stored for >20 days (mean age 28 days) compared
with RBCs stored for <5 days (mean age 2 days). In addition,
this study again showed a lack of improvement in tissue
oxygenation after RBC transfusion.93 Owing to the metho-
dological limitations of this single-centre study, it was again
stated that large prospective multicentre clinical trials are
needed to define the role of RBC age on outcome.56
Studies evaluating the outcome of RBC transfusions
Although numerous studies have addressed the effects of
RBC transfusions, only one randomized controlled trial
(RCT), the Transfusion Requirements in Critical Care
(TRICC) Trial,32 had sufficient power to evaluate the effect
of transfusions on morbidity and mortality.12 This study,
conducted by He´bert and colleagues,32 enrolled 838 criti-
cally ill patients who were admitted to the ICU with an initial
haemoglobin concentration >9 g dl1. The patients were
randomized to either a restrictive transfusion strategy
with a transfusion trigger of 7 g dl1 (target haemoglobin
concentration, 7–9 g dl1) or a liberal transfusion strategy
with a transfusion trigger of 10 g dl1 (target haemoglobin
concentration, 10–12 g dl1). Thirty-day mortality was
slightly lower in the restrictive transfusion group (18.7%
versus 23.3%), although statistical significance was not
reached (P=0.11). However, subgroup analyses of patients
who where less acutely ill, as defined by the APACHE II
score, or who were aged >55 yr showed a significantly lower
30-day mortality in the restrictive transfusion group. In addi-
tion to the TRICC trial, Carson and colleagues12 identified
nine other RCTs that used a clearly defined restrictive or
liberal transfusion strategy, giving a total number of 1780
patients in 10 trials. Transfusion protocols used in these
studies were different, resulting in overlapping transfusion
triggers. The clinical settings were also different, which may
partly explain the variability in terms of effect size of the
clinical outcomes, particularly concerning the effect of
restrictive transfusion thresholds on the use of blood trans-
fusions.12 Apart from the TRICC trial, only two other studies
comparing different transfusion thresholds included more
than 100 patients.8 47 However, the differences in postopera-
tive haemoglobin levels were not significantly different8 or
were very small.47 There was no47 or very little mortality,
which was not significantly different between the two trans-
fusion strategies.8 Consequently, a meta-analysis of these
studies was dominated by the TRICC trial which contributed
more than 80% of the observed deaths in the mortality
analysis.12 35 There were also no significant differences in
morbidity and LOS.
The results of these RCTs have to be compared with the
results of observational studies evaluating the effect of
anaemia and blood transfusion strategies on morbi-
dity and mortality. Again, there is a considerable hetero-
geneity concerning the clinical setting among these
studies. Among 10 observational studies conducted to
date,10 15 33 37 58 62 81 90 91 99 the six largest included patients
in the ICU,15 33 90 91 orthopaedic surgery10 and cardiac sur-
gery.81 The conclusions are contradictory. The recently pub-
lished CRIT study (Anaemia and Blood Transfusion in the
Critically Ill—Current Clinical Practice in the United States)
enrolled 4892 patients from August 2000 to April 2001,15
44.1% of whom were transfused with one or more RBC units.
Mean pretransfusion haemoglobin was 8.6 (SD1.7) g dl1.
The number of RBC units transfused was an independent
risk factor for mortality and LOS. In addition, patients who
were transfused had more complications and were more
likely to experience complications. A very similar study,
the ABC study (Anemia and Blood Transfusion in the
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35
Critically Ill), was performed in European ICUs.90 Similar to
the CRIT study, 37.0% of the 3534 patients (enrolment from
November 15 to November 29, 1999) were transfused with a
mean pretransfusion haemoglobin of 8.4 (1.7) g dl1.
Mortality was higher for transfused patients than for non-
transfused patients with similar organ dysfunction as
assessed by the Sequential Organ Failure Assessment
(SOFA) score. After matching patients by propensity scores
(i.e. probability) for being transfused (and thus controlling,
amongst other variables, for SOFA and APACHE II score),
28-day mortality was significantly higher in patients with
transfusions (22.7% versus 17.1%, P=0.02). The most
recently conducted study, the SOAP study, enrolled 3147
patients between May 1 and May 15, 2002,91 of whom 33%
received an RBC transfusion. Patients receiving transfusions
were older and generally sicker. Therefore it is not surprising
that mortality rates were higher in transfused patients.
Similarly, higher transfusion rates were associated with
higher mortality. However, after propensity matching,
mortalityrateswere thesameintransfusedandnon-transfused
patients, with a tendency towards lower survival in non-trans-
fused patients. Thus the SOAP study contrasts with the CRIT
and ABC studies; this could be due to the implementation of
deleucocytation in Europe, as the authors suggested.91
The largest observational study included 8787 consecu-
tive hip fracture patients, aged >60 yr, who underwent
surgical repair between 1983 and 1993.10 There was no
influence of perioperative RBC transfusion on 30- or 90-
day mortality in patients with a haemoglobin concentration
>8 g dl1. The effect of a transfusion on mortality in
patients with a haemoglobin concentration <8 g dl1
could not be calculated since 90.5% of these patients,
who made up only 12.7% of the whole study population,
receiveda transfusion. Inaddition to thepossibility thatpoten-
tial confounders were missed (a problem which is inherent in
all observational studies), the authors identified a number of
other limitations that have to be considered when interpreting
these results.10 However, these results indicate that transfu-
sionathaemoglobin levels>8gdl1maynot improvesurvival
in elderly patients with a high illness burden.
What is the evidence from these RCTs and
observational studies?
The validity of the observational studies is not clear because
sicker patients are more likely to be transfused.77 Although
statistical analysis tried to control for potentially confound-
ing factors (e.g. in the CRIT and ABC studies), this adjust-
ment could only be made for the variables recorded. Thus,
given the complex pathophysiology of critical illness, it is
possible that comorbidity was not sufficiently adjusted for in
these observational studies. Consequently, they only allow
conclusions about associations between factors and not
about causality. However, one key question still remains
to be answered: Why does there seem to be a relationship
between RBC transfusions and worse clinical outcome in
some studies such as the CRIT and ABC studies, and
why does the more recently conducted SOAP study
contradict them?
One issue that is currently under substantial debate is
universal leucoreduction.68 Compared with buffy-coat-
free RBCs, the use of a leucocyte filter results in a 3 log
reduction of leucocytes to approximately 106/RBC unit.16
The observation that RBC transfusions may be linked to
immunosuppression was made more than 30 years ago.61
Since then, particular interest has been directed towards the
contribution of white blood cells (WBCs) to transfusion-
associated immunomodulation (TRIM).7 Numerous obser-
vational studies and RCTs have been performed examining
the immunomodulatory effect of allogeneic RBC transfu-
sions and the effect of WBC reduction.86 A meta-analysis of
RCTs examining the association between allogeneic RBC
transfusion and postoperative infection could find no differ-
ence between WBC-reduced and buffy-coat-reduced
blood.84 In contrast, transfusion of non-buffy-coat-reduced
allogeneic RBCs (or whole blood) was associated with
increased risk for postoperative infection. However, this
conclusion was based on three heterogenous studies and
therefore was not very convincing, prompting the author
to call for further RCTs investigating TRIM of non-
buffy-coat-reduced (or whole blood) versus WBC-reduced
allogeneic RBC transfusions.84 A before-and-after cohort
study in Canada found a reduction in mortality, post-
transfusion fevers and antibiotic use after implementation
of a universal leucoreduction programme.29 In contrast, a
recent meta-analysis by Vamvakas85 did not find an associa-
tion between WBC-containing allogeneic (compared with
WBC-reduced allogeneic or autologous) RBC transfusions
and mortality. Subgroup analyses of this meta-analysis
suggested that there may be an association between
WBC-containing allogeneic RBC transfusions and short-
term mortality in the setting of open-heart surgery and
when WBC-containing allogeneic RBC transfusions are
compared to prestorage-filtered WBC-reduced RBC trans-
fusions.85 However, these associations were not very strong.
A recent prospective cohort-controlled study observed a
decrease in LOS in open-heart surgery with leucoreduced
blood transfusions.22 In contrast, a before-and-after study in
the UK observed no impact on LOS and postoperative infec-
tion in orthopaedic and cardiac surgery,46 thus adding addi-
tional contradictory conclusions to this ongoing debate.
In view of this huge controversy, it is interesting to note
that the major difference between the two large European
observational studies, the SOAP study and the ABC study,
was that leucoreduction was much more common in 2002
than in 1999.98 At the time of inclusion of the patients for the
ABC study, Germany, Holland, Norway and Finland who
together contributed about one-third of the 3534 patients,
had not started implementation of universal leucoreduction,
while other participating countries were just completing it.98
Additionally, the authors stated that 46% of the ICUs used
leucocyte-depleted blood most of the time, 35% some of the
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time and 19% never.90 Thus the contradictory results of
these two studies may suggest a possible role of leucocytes
in causing adverse clinical outcomes after RBC transfusion.
However, this is purely speculative and therefore it will be
important to see the outcomes of future large RCTs evalu-
ating different transfusion thresholds, comparable to the
TRICC trial but with WBC-reduced blood.
In addition, the age of RBC units may be another impor-
tant factor influencing the efficacy of RBC transfusion as
outlined above. Thus a lack of control of this factor may be
another reason for these contradicting results.
Tolerance to anaemia–RBC transfusions
in patients at risk
The so-called ‘10/30 rule’, meaning that an RBC transfusion
was indicated below a haemoglobin concentration of
10 g dl1 or a haematocrit below 30%, has served as a
transfusion trigger for many years. However, on the one
hand this rigid numerical transfusion trigger totally neglects
individual patient factors and the underlying pathophysio-
logical consequences determining each patient’s individual
tissue oxygen demands. On the other hand it does not reflect
the capacity of human tolerance to anaemia. In a case report
of an 84-yr-old Jehovah’s Witness, the critical haemoglobin
concentration (Hbcrit) at which DO2 was reached was about 4
g dl1. A review of the literature on Jehovah’s Witnesses
identified 134 medical and surgical patients with a haemo-
globin concentration <8 g dl1 or a haematocrit <24%.89
Fifty deaths were reported among these 134 patients, of
which 23 were attributed exclusively or primarily to
anaemia. All these patients, with the exception of three
with cardiac disease who died after cardiac surgery and
two with missing laboratory data, died with a haemoglobin
concentration <5 g dl1 or an equivalent haematocrit.
Notably, this value was also found in 27 of the survivors.
Weiskopf and colleagues96 showed in 32 healthy volunteers
and patients that acute isovolaemic haemodilution to a
haemoglobin concentration <5 g dl1 did not induce an
inadequate systemic DO2. These results further supported
the assumption of a critical haemoglobin concentration of
<5 g dl1 in healthy human beings. They also support the
most recent recommendations defining a haemoglobin
concentration <6 g dl1, which is close to the critical
haemoglobin concentration reported in the literature, as a
transfusion trigger.2 Furthermore, in a haemoglobin concen-
tration range of 6–10 g dl1, they propose an individual
assessment of each patient’s risk for complications of inad-
equate oxygenation. A number of clinical risk factors which
may decrease a patient’s tolerance to anaemia and thus
increase the critical haemoglobin concentration have been
identified.48 Patients with coexisting cardiovascular disease
(CVD) may be at particular risk. In coronary artery disease
(CAD), an adequate increase in the coronary blood flow in
response to a decrease in haemoglobin concentration is not
possible and myocardial ischaemia may develop. In
addition, impaired myocardial contractility may limit the
compensatory increase in CO. A retrospective cohort
study in 1958 patients who declined blood transfusions
for religious reasons corroborated this hypothesis.11 It
was found that below a preoperative haemoglobin concen-
tration of 10–11 g dl1 the mortality increased in patients
both with and without CVD, but more in the CVD group.
Similarly, in a subgroup analysis of an observational study
evaluating the effect of anaemia and blood transfusion stra-
tegies on mortality, He´bert and colleagues33 found an asso-
ciation between anaemia and risk of death in critically ill
patients with cardiac disease. They detected an improved
survival in this subgroup of patients with increasing haemo-
globin values (odds ratio 0.80 [95% CI 0.66–0.97] for each
1.0 g dl1 increase starting from a pretransfusion haemo-
globin concentration <9.5 g dl1, P=0.01). In contrast with
these findings, a subgroup analysis of the TRICC trial
showed no differences in mortality rate between the restric-
tive and the liberal transfusion strategies in patients with
CVD.34 Although the authors were aware of the possible
limitations of this subgroup analysis, they suggested that
a transfusion trigger of 7 g dl1 would be safe in critically
ill patients with CVD.34 Possible exceptions were patients
with acute myocardial infarct and unstable angina. Taking
these studies together, recent reviews on this topic con-
cluded that Nevertheless, as is necessary in healthy patients,
clinical signs of inadequate oxygenation should guide trans-
fusion decisions.2 74 In the case of patients with CVD, new
ST-segment depression >0.1 mV, new ST-segment elevation
>0.2 mV or new wall motion abnormalities on transoesopha-
geal echocardiography may represent signs of inadequate
oxygenation of the myocardium.74 However, more studies,
particularly large RCTs, are required to clarify transfusion
requirements in this important subgroup of patients.
Transfusion-associated risks
Transfusion-related risks can be divided into transfusion-
transmissible infections (TTIs), immunological risks and
mistransfusion.
Infectious risks
RBC transfusion in Western countries has probably
never been safer than today with respect to transfusion-
transmissible viruses such as HIV, hepatitis B virus (HBV)
and hepatitis C virus (HCV).49 The estimated risks of
infection have dramatically decreased over recent years as
increased test sensitivity has reduced the infectious window
periods.23 Estimates of current risk are shown in Table 1.
In contrast with Western countries, viral TTIs are a major
problem in countries with a low human development index
(HDI), which is an index based on life expectancy, literacy,
enrolment in higher education and per capita income
(Table 1). A high seroprevalence of these diseases in the
general population of these countries, poorly organized
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blood donation systems and poor sensitivity of pathogen
testing are important factors.49 Future transfusion practice
in low HDI countries will strongly depend on international
investment to guarantee appropriate transfusion safety.5
Compared with viral TTIs, there is much more concern
about transfusion-transmitted bacterial infections (TTBIs)
and post-transfusion sepsis92 in high HDI (Western) coun-
tries. Contamination of platelets is more common than trans-
fusion of bacteria-containing RBC units. This is due to the
platelet storage temperature of 20–24C which favours bac-
terial growth, in contrast with RBCs that are stored at 4C.
Best risk estimates of TTBIs from a Canadian study gave
values in the range of about 1:2000 to 1:8000 (13–44 per
100 000) for platelet pools and 1:28 000 to 1:143 000
(0.7–3.6 per 100 000) for transfused RBC units.42 Notably,
when comparing the frequency of TTBIs from different
studies, the differing stringency of criteria for the diagnosis
of TTBI should be considered.42
Variant Creutzfeld–Jakob disease
Recently, the first possible cases of transfusion-transmitted
variant Creutzfeld–Jakob disease (vCJD) have been
reported.45 63 The probability that the first case of vCJD
was not due to transfusion-transmitted vCJD ranged from
1:15 000 to 1:30 000. The hypothesized incubation period of
transfusion-transmitted vCJD was 6.5 yr.45 The UK’s sec-
ond case of vCJD possibly transmitted by a blood transfu-
sion may have been caused by blood administered in 1999.63
This patient died of causes unrelated to vCJD. As with the
first case, this patient was the recipient of non-leucodepleted
RBCs from a donor who developed symptoms of vCJD after
donation. A post-mortem examination revealed the presence
of prion proteins in the patient’s spleen and cervical lymph
node but not in gut-associated lymphoid tissue and tonsil,
which suggests an intravenous rather than an oral route of
transmission.63 This led the UK government to extend its
ban, which initially excluded anyone who had received a
blood transfusion since January 1980 from blood donation,
to cover a larger group of transfusion recipients.64 The latest
ban, which came into operation in April 2004, has reduced
the number of donors in the UK by 3.3%.1 Since 1999, the
pool of blood donors in the UK has fallen by over 20% and
currently stands at 1.64 million.1 The impact of the extended
ban, which will become effective from April 2005, remains
to be seen. Taking into account the incubation period of
6.5 yr in the first case, asymptomatic vCJD patients with
such a long incubation period could represent a significant
source of iatrogenic infection by blood donation or
contamination of surgical instruments.63 Interestingly, it
has been shown that leucoreduction is efficacious in
reducing white-cell-associated transmission of spongiform
encephalopathies but fails to eliminate it.25 In addition, some
infectivity of transmissible spongiform encephalopathies
(TSEs) is assumed to be plasma associated.25 The policy
of leucoreduction aimed at reducing TSE infectivity may
require re-evaluation.
Immunological risks
In contrast with low HDI countries, which are very con-
cerned with TTIs, immunological transfusion reactions
are generally more frequently encountered in high HDI
countries49 (Table 1).
As already outlined, RBC transfusions seem to have an
immunomodulatory effect, the causes of which are not very
well understood. Although several studies have suggested
that WBCs cause immunomodulation, the blood compo-
nents that mediate this effect are still not defined. It
is beyond the scope of this review to discuss all immuno-
logical risks in detail. Therefore the reader is referred to a
comprehensive review on risks associated with RBC
Table 1 Transfusion-associated risks (modified according to Marcucci and colleagues49)
Type of risk Estimate of current risk (infection rate per unit)
High HDI countries Low HDI countries
Infections
Viruses
HIV 1:1 468 00017–1:4 700 00042 1:5053–1:25789
HBV 1:31 00042–1:205 00017 1:74–1:10004
HCV 1:1 935 00017–1:3 100 00042 1:25789
Bacteria (contamination) 1:2000–1:8000 (platelet pools)/1:28 000–1:143 000 (red cells)42 ?
Parasites
Malaria 1:4 000 00042 1:341
Prions
vCJD First two possible transmissions described46 63 ?
Immunological reactions
Haemolytic transfusion reactions
Acute haemolytic 1:13 00042 ?
Delayed haemolytic 1:900042 ?
Alloimmunization 1:160042 ?
Autoimmunization ? (recently identified as risk)100 ?
Immunosuppression 1:139 ?
TRALI 1:70 00042 ?
Mistransfusion 1:14 000–1:18 00023 42 ?
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transfusions in Canada.42 However, the reader’s attention
should be directed towards one complication that is contro-
versial: transfusion-related acute lung injury (TRALI).
According to the Serious Hazards of Transfusion (SHOT)
Annual Report,3 in 2003 there were 36 suspected cases in the
UK and RBCs were implicated in five of these. This corre-
sponds to one implicated case per 529 000 RBC units trans-
fused (0.2:100 000 RBC units),3 whereas Canadian data
from 1998 gave a risk estimate of 1.4:100 000 RBC units
transfused,42 and estimates from the USA are as high as
1:5000 RBC units transfused.24 Thus there is considerable
uncertainty as to the incidence of TRALI since under-report-
ing is thought to be a problem.42 94 This may be due to lack of
awareness or the difficulty in diagnosis, as the symptoms and
signs of TRALI may be confused with other conditions such
as adult respiratory distress syndrome, volume overload or
congestive heart failure. The most urgent issue concerning
TRALI is the need for a standardized definition which would
allow reliable statements about incidence and comparison
between hospitals.94
Mistransfusion
Mistransfusion is estimated to occur in 1:14 000 to 1:18 000
transfusions and thus is one of the most frequent transfusion
hazards in HDI countries.23 42 97 To make matters worse,
mistransfusion is associated with significant morbidity
and mortality.97
Transfusion alternatives
As already outlined, allogeneic RBC transfusions bear con-
siderable risks, have possible adverse clinical outcomes and
are of questionable efficacy. In addition, they are expensive
and susceptible to shortages. Thus blood conservation stra-
tegies are crucial for a reduction in the need for allogeneic
RBC transfusion.73 There are different options for the
pre-, intra- and postoperative periods.
Preoperatively, autologous blood donation (ABD) and the
use of recombinant human erythropoietin (EPO) are of
value. ABD has most benefit in patients who undergo sur-
gical procedures with a high estimated blood loss such as
orthopaedic joint replacement surgery. In a retrospective
study in 9482 patients with total joint (hip and knee) replace-
ment surgery, about 28% of patients who had not predonated
blood received allogeneic RBC transfusion compared with
only 9% of all the patients having ABD. In the subgroup of
mildly anaemic patients (haemoglobin concentration of
10–13 g dl1) having ABD, the rate of allogeneic RBC
transfusions increased to about 15%.6 However, only 55%
of the predonated blood units were given back to the
patients,6 which explains the poor cost-effectiveness of
ABD.18 The stimulant effect of EPO on RBC production
starts to become efficacious after 5–7 days. Therefore EPO
clearly has its place in the preoperative preparation of the
anaemic surgical patient.66 It reduces the need for allogeneic
blood transfusions and can effectively be combined with
other blood conservation techniques.52
Intraoperatively, acute normovolaemic haemodilution
(ANH),40 cell salvage,21 pharmacological haemorrhage
control,38 anaesthesia and surgical techniques, acceptance
of minimal haemoglobin levels and artificial oxygen
carriers14 73 75 can be used to avoid allogeneic RBC
transfusion.66 73
Postoperatively, cell salvage, acceptance of minimal hae-
moglobin levels and pharmacological haemorrhage control
can be used.73
Transfusion guidelines
As mentioned earlier, haemoglobin-based transfusion trig-
gers do not take into account the individual patient’s ability
to tolerate and compensate for anaemia. Therefore appro-
priate transfusion guidelines should be based primarily on
physiological transfusion triggers, whereas haemoglobin-
based transfusion triggers should serve as an aid in cases
of insufficient or unreliable information on the patient’s
global or regional tissue oxygenation. What are the useful
signs of inadequate global or regional tissue oxygenation
that can be incorporated into guidelines as physiological
transfusion triggers?
Before applying physiological transfusion triggers, it is
important to rule out hypovolaemia, optimize anaesthesia,
and correct any pre-existing tachycardia. Global signs of
inadequate oxygenation are haemodynamic instability
with relative tachycardia and hypotension,72 80
O2ER>50%,70 72 78 a mixed venous oxygen saturation
(Svo2 ) <50%,
72 a low mixed venous oxygen partial pressure
(Pvo2 )
70 72 and a decrease in VO2.
70 72 Different thresholds
have been proposed for Pvo2 and VO2.
70 In their guidelines,
the College of American Pathologists suggested Pvo2
<25 mm Hg and a decrease of >50% in VO2 as physiological
transfusion triggers.70 These transfusion triggers are prob-
ably too restrictive, since they have been shown to be
reached only after circulatory failure.55 In accordance
with experimental83 and clinical88 results, a transfusion trig-
ger of Pvo2<32 mm Hg seems to reflect better the threshold
at which Do2crit is reached. Similarly, a decrease in VO2 of
>10% should serve as a safer transfusion trigger.73
With respect to impaired regional oxygenation, there is
most concern about myocardial ischaemia. New ST-segment
depression >0.1 mV or new ST-segment elevation >0.2 mV
for more than 1 min in continuous five-lead ECG monitoring
and new wall motion abnormalities detected by trans-
oesophageal echocardiography may be signs of myocardial
ischaemia.74 Importantly, this haemodilution-associated
myocardial ischaemia can be reversed by a small increase
in haemoglobin concentration79 or a decrease in heart rate.44
Transfusion indications based on physiological and numer-
ical transfusion triggers are shown in Table 2.
Conclusions
There is now general agreement that transfusion decisions
should be primarily based on an individual patient’s need for
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global and regional oxygen supply as indicated by signs of
inadequate global and regional oxygenation. These physio-
logical transfusion triggers based on the individual patient’s
characteristics make a thorough knowledge of transfu-
sion physiology and clinical experience indispensable. How-
ever, numerical transfusion triggers may be helpful in
certain situations such as when monitoring is inadequate
or there is a lack of sufficiently experienced medical
personnel.
Current evidence from studies of the influence of allo-
geneic blood transfusion on efficacy and clinical outcome is
seriously hampered by the absence of a significant number of
adequately powered RCTs. In addition, the only large RCT
that compared a restrictive versus a liberal transfusion strat-
egy, the TRICC trial, was done in ICU patients. There has
been no sufficiently powered RCT in the perioperative set-
ting. Therefore the findings from the frequently cited obser-
vational studies (ABC and CRIT study) and the TRICC trial
can only be extrapolated with caution to perioperative trans-
fusion decisions. Furthermore, ‘hot topics’ in transfusion
medicine that have to be addressed by future large RCTs
are the effect of different transfusion thresholds on morbid-
ity and mortality, particularly in the perioperative setting
and in CVD patients, the impact of RBC storage on
transfusion efficacy and the role of leucoreduction.
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